Introduction
============

The term metabolic syndrome (MES), also known as the insulin resistance syndrome or syndrome X refers to a group of correlated disorders that include insulin resistance, glucose intolerance, obesity, dyslipidemia, and hypertension ([@b1-ijph-41-70]). It is well known that in the general population, metabolic syndrome (MES) is associated with increased cardiovascular morbidity ([@b2-ijph-41-70]), mortality ([@b3-ijph-41-70]) and high incidence of type 2 diabetes mellitus ([@b4-ijph-41-70]). Cardiovascular diseases (CVD) are one of the major causes of mortality in Iran ([@b5-ijph-41-70]). Although there are varying definitions for the MES by several health organizations, the basic components remain constant and include abdominal obesity, hypertension (HTN), atherogenic dyslipidemia, and glucose intolerance or diabetes. Metabolic syndrome by the NCEP definition is associated with a 1.7-fold increase in CVD risk ([@b6-ijph-41-70]).

Although there are some reports regarding the prevalence of MES in Iran ([@b7-ijph-41-70]--[@b10-ijph-41-70]), but the precise prevalence of it is unknown and may vary from area to area. The aim of the present study was to determine the prevalence of the metabolic syndrome in Zahedan, southeast Iran.

Materials and Methods
=====================

This population based descriptive cross-sectional study was performed on 1802 individuals (735 male, 1067 female) from September 2008 to March 2009 in Zahedan, southeast, Iran. The sample size calculation was done based on the assumption that the prevalence of MES to be approximately 33% according to the finding of Zabetian et al. ([@b7-ijph-41-70]). Samples were selected by random cluster sampling from 20 regions of Zahedan. The study was approved by the local Ethics Committee of Zahedan University of Medical Sciences and written informed consent was obtained from all subjects.

Face-to-face interviews using structured questionnaires the following were collected: demographic data (date of birth, contact information, medical history, current medications, family history, length of residence in the Zahedan); height (by a stadiometer using a centimeter scale), weight (by a clinical scale); waist circumference (by a tape measure just upper the superior iliac crest with the subject standing, at the end of normal expiration); blood pressure (by a mercury sphygmomanometer with the subject sitting); and 5 ml of venous blood drawn after 8--12 h fasting for laboratory tests.

The blood samples were collected in tubes and sera were obtained. Samples were stored at −80 ºC until further biochemical analysis. Biochemical analysis (fasting blood glucose, triglyceride, HDL-cholesterol) was assayed using a commercially available kit.

The prevalence of metabolic syndrome among 1802 individuals was determined according to NCEP ATP III ([@b11-ijph-41-70]), IDF ([@b12-ijph-41-70]) and IDF-AHA/NHLBI ([@b13-ijph-41-70]) criteria as shown in [Table 1](#t1-ijph-41-70){ref-type="table"}.

Furthermore, we calculated the cut-off values for WC in men and women in our population for determination the prevalence of MES.

Statistical analysis was performed using SPSS version 17. Results are expressed as mean ±S.D. for quantitative variables and as frequency (%) for otherwise. A *P* value \<0.05 was considered statistically significant.

Receiver operating characteristic (ROC) curves were used to determine the cut-off values for WC ([Fig. 1](#f1-ijph-41-70){ref-type="fig"}). The optimum cut-off value was determined by selecting the point that provided the greatest sum of sensitivity and specificity.

Results
=======

Clinical characteristics of our population individuals (n=1802; men=735, women=1067) is shown in [Table 2](#t2-ijph-41-70){ref-type="table"}. There was a significant differences regarding blood pressure (systolic and diastolic), weight, height, BMI, waist circumference, triglyceride, and HDL-C among men and women (*P*\<0.05), while there was not significant differences regarding fasting blood glucose.

The prevalence of MES according to NCEP ATP III, IDF and IDF-AHA/NHLBI criteria is shown in [Table 3](#t3-ijph-41-70){ref-type="table"}. In our population the prevalence of MES was 21.0%, 24.8% and 23.3% based on NCEP ATP III, IDF and IDF-AHA/NHLBI criteria, respectively. In addition the prevalence of MES was significantly higher in women (NCEP ATP III=24.9%; IDF=28.1%, IDF-AHA/NHLBI=25.8) than men (NCEP ATP III=15.4%; IDF=20.0%; IDF-AHA/NHLBI=19.7). Age related increase in the prevalence of metabolic syndrome was observed in both of the genders ([Fig. 2](#f2-ijph-41-70){ref-type="fig"}).

Percentage of the individual component of metabolic syndrome in our population was shown in [Fig. 3](#f3-ijph-41-70){ref-type="fig"}. In our population, 13% had hypertension, 43.3% had central obesity, 32.0% had high triglyceride, 60.6% had low HDL-C and 17.1% had hyperglycemia.

In women, abnormal BP, central obesity, high triglyceride, low HDL-C and hyperglycemia occurred in 11%, 49.8%, 26.4%, 75.2% and 16.4%, respectively. In men, abnormal BP, central obesity, high triglyceride, low HDL-C and hyperglycemia occurred in 16.1%, 34.0%, 40.3%, 39.5 % and 18.2%, respectively.

Overall, low serums HDL-C and central obesity were the most common risk factors, whereas hyperglycemia was the least common.

In addition we found that in our population, 16.2% of subjects had no risk factors, 35.3% of subjects had one, 23.5% had two, and 17.3% had three, 6.2% had four and 1.4% had five risk factors.

We found that the optimal cut-off point of WC for the prediction of at least two components of MES as defined by IDF was 93.5 cm for men (sensitivity=59.27%, specificity=78.85%) and 85.5 cm for women (sensitivity=75.79%, specificity=62.78%).

Discussion
==========

The present study showed that the prevalence of MES was 21.0%, 24.8% and 23.3% based on NCEP-ATPIII, IDF and IDF-AHA/NHLBI, respectively.

Metabolic syndrome is defined as a cluster of metabolic risk factors including central obesity, glucose intolerance, dyslipidemia, and elevated blood pressure. The most widely accepted criteria are those proposed earlier ([@b11-ijph-41-70]). The IDF criteria for MES was based on the same parameters used in the NCEP criteria, the former identified central obesity as an essential component for MES ([@b12-ijph-41-70]).

There are some reports regarding the prevalence of MES in different parts of Iran. The prevalence of the metabolic syndrome was 6.5% among 15 to 17 year old adolescent girls in Mashhad, Iran ([@b14-ijph-41-70]), 50.8% in Iranian women aged ≥65 years who participated in the Tehran Lipid and Glucose Study ([@b8-ijph-41-70]), 34.7% based on the ATP III criteria ([@b15-ijph-41-70]), and 33.2% by the ATPIII criteria in men and women aged ≥20 years participated in the cross-sectional phase of the Tehran Lipid and Glucose Study ([@b7-ijph-41-70]). In addition, the prevalence of MES was 10.1% in a population-based cross-sectional study of 3036 Iranian adolescents (1413 boys and 1623 girls) 10 to 19 years ([@b16-ijph-41-70]), 39.9% (ATP III; male: 29.1% and female: 50.4%), 40.5% (IDF; male: 26% and female: 54.5%) in Greater Khorasan Province of Iran ([@b17-ijph-41-70]), 31.1% in adults population of Tehran ([@b18-ijph-41-70]), 27% in Tehran where WC cut-off point was 91.5 cm in men and 85.5 cm in women ([@b10-ijph-41-70]). Cut-off point of WC for predicting at least two other components of the metabolic syndrome as defined by the IDF was 89 cm for men and 91 cm for women in Iran ([@b15-ijph-41-70]). In the present study we found WC cut-off points of 93.5 cm for male and 85.5 cm for female which is different with former study ([@b15-ijph-41-70]). The prevalence of MES in the Irish population according to the ATPIII and IDF criteria was 13.2% and 21.4%, respectively ([@b19-ijph-41-70]), in urban Pakistan according to the IDF definition and modified ATP III criteria was 34.8% and 49%, respectively ([@b20-ijph-41-70]), among adult Qatari population was 26.5% and 33.7% ([@b21-ijph-41-70]) and 15--30% among Korean adults ([@b22-ijph-41-70]). The prevalence of metabolic syndrome is low in rural Japan as 4.6% in males and 4.2% in females ([@b23-ijph-41-70]). The investigators concluded that the lower prevalence of MES may be due to the consumption of traditional Japanese food.

One reason of such differences among various studies may be due to criteria used to define MES (e.g. ATP III vs. IDF, Waist to hip ratio vs. abdominal obesity) but most probably might be due to heterogeneity of population.

Prevalence of MES based on IDF criteria was higher than NCEP ATPIII criteria because of high dependence of diagnosis of MES to abdominal obesity in IDF criteria. The higher rate of MES in women may be largely due to the lower physical activity which may also explain the higher prevalence of MES in aged individuals.

In conclusion, the findings of our population-based study showing a high prevalence of the metabolic syndrome in Southeast of Iran which has implications for diabetes and cardiovascular prevention programs.
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###### 

Criteria for diagnosis of the metabolic syndrome

  **Criterion**                 **ATP III panel [\*](#tfn1-ijph-41-70){ref-type="table-fn"}**   **IDF panel[†](#tfn2-ijph-41-70){ref-type="table-fn"}**   **IDF -AHA/NHLBI[\*](#tfn1-ijph-41-70){ref-type="table-fn"}**
  ----------------------------- --------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------
  **Waist (cm)**                                                                                                                                          
    Male                        ≥102                                                            ≥94                                                       ≥94
    Female                      ≥88                                                             ≥80                                                       ≥80
  **HDL (mg/dL)**                                                                                                                                         
    Male                        \<40                                                            \<40                                                      \<40
    Female                      \<50                                                            \<50                                                      \<50
  **Triglyceride (mg/dL)**      ≥150                                                            ≥150                                                      ≥150
  **Fasting Glucose (mg/dL)**   ≥100                                                            ≥100                                                      ≥100
  **Blood pressure (mmHg)**     ≥130/85                                                         ≥130/85                                                   ≥130/85

Three of five required.

Central adiposity required; two of subsequent four required.

###### 

Clinical characteristic of the 1802 subjects

                             **Total (n=1802)**   **Men^a^ (n=735)**   **Women^b^ (n=1067)**   ***P* value a versus b**
  -------------------------- -------------------- -------------------- ----------------------- --------------------------
  **Age (yr)**               35.85±13.81          37.46±14.89          34.91±13.17             \<0.0001
  **Systolic BP (mmHg)**     116.22 ±16.53        119.92±15.70         113.63±16.61            \<0.0001
  **Diastolic BP (mmHg)**    74.02±11.95          76.43±11.47          72.35±11.99             \<0.0001
  **Weight (kg)**            64.64±14.06          68.66±13.85          61.88±13.54             \<0.0001
  **Height (cm)**            162.43±9.92          170.42±8.00          156.92±6.92             \<0.0001
  **BMI (kg/m^2^)**          24.52±5.02           23.64±4.48           25.13±5.28              \<0.0001
  **Waist (cm)**             86.45±14.63          87.91±14.19          85.44±14.84             \<0.0001
  **Triglyceride (mg/dL)**   139.81±110.41        158.24±132.19        127.10±90.36            \<0.0001
  **HDL-C (mg/dL)**          45.03±8.48           43.65±7.81           45.98±8.78              \<0.0001
  **FBG (mg/dL)**            90.90±29.99          92.35±30.78          89.90±29.41             0.103

###### 

Prevalence of metabolic syndrome according to NCEP-ATPIII, IDF and IDF-AHA/NHLBI criteria

  **Criteria**            **Total**   **Men**   **Women**
  ----------------------- ----------- --------- -----------
  **NCEP ATP III (%)**    21.0        15.4      24.9
  **IDF (%)**             24.8        20.0      28.1
  **IDF-AHA/NHLBI (%)**   26.4        22.9      28.8
